Research programme: anti-HIV microbicides - GlaxoSmithKline/IPM

Drug Profile

Research programme: anti-HIV microbicides - GlaxoSmithKline/IPM

Alternative Names: Anti-HIV microbicides research programme - GlaxoSmithKline/IPM

Latest Information Update: 13 Mar 2008

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; International Partnership for Microbicides
  • Class
  • Mechanism of Action Virus internalisation inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 13 Mar 2008 No development reported - Preclinical for HIV infections in USA (Vaginal)
  • 12 Oct 2004 Preclinical trials in HIV infections prevention in USA (Vaginal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top